



WEBINAR: Peptide Receptor Radiotherapy for Neuroendocrine Tumors

Tuesday, October 20, 2015 | 12:00pm ET | [Register Now](#)*

**If you cannot see the event, please click on "Event Center"*

Join Josh Mailman, Edward Wolin, MD and Erik Mittra, MD, PhD for an informative webinar on Peptide Receptor Radiotherapy for Neuroendocrine Tumors.

Learn **what** PRRT is, **how** it works, **where** it is being used, **and who** is eligible to receive it.

About the Speakers:

	<p>Josh Mailman President NorCal CarciNET</p>	<p>Josh is an extremely active member of the NET, Nuclear Medicine and Integrative Medicine communities, serving as President of the NorCal CarciNET Community, Past Chair of the Patient Advocate Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), co-Chair of the Patient Advocate Taskforce for the Society for Integrative Oncology (SIO) and a member of the National Cancer Institute's taskforce on NETs. He also served on the Executive Board of the SIO from 2009-2013.</p>
	<p>Edward M. Wolin, MD Director of Neuroendocrine and GI Oncology Director of Clinical Research University of Kentucky Lexington, KY</p>	<p>Dr. Wolin is the Director of Neuroendocrine and GI Oncology and Director of Clinical Research at the University of Kentucky Markey Markey Cancer. His research efforts focus on finding treatments which are more effective and less toxic, including pasireotide, lanreotide, everolimus, other m-tor inhibitors, targeted radiation including PRRT with Lu-177, anti-angiogenic drugs, novel targeted biologic anti-cancer treatments, and targeted treatment of liver metastases. His research is also directed at development of new imaging and diagnostic procedures for carcinoid/neuroendocrine tumors.</p>
	<p>Erik Mittra, MD, PhD Clinical Assistant Professor Department of Radiology & Nuclear Medicine Stanford University Medical Center Stanford, CA</p>	<p>Dr. Mittra is a Clinical Assistant Professor of Radiology at Stanford University Medical Center. He finished his residency in Nuclear Medicine and fellowship in PET/CT also at Stanford University, and is board certified in Nuclear Medicine. Dr. Mittra is the Principal Investigator of the Phase III PRRT Trial at Stanford University, and has a very active interest in Targeted Radiotherapies for many types of cancer, including neuroendocrine tumors.</p>